Showing 3011-3020 of 5771 results for "".
- Abigail Markward Named Executive Director of ASOAhttps://modernod.com/news/abigail-markward-named-executive-director-of-asoa/2482399/The American Society of Ophthalmic Administrators (ASOA) has announced the appointment of Abigail Markward, MBA, as its new executive director, effective immediately. In addition to this new role, Ms. Markward will continue her responsibilities as executive director of the ASCRS Foundation, a pos
- Ocumension Therapeutics Secures Deal with Alcon to Expand Dry Eye Treatment Portfolio in Chinahttps://modernod.com/news/ocumension-therapeutics-secures-deal-with-alcon-to-expand-dry-eye-treatment-portfolio-in-china/2482395/China-based ophthalmic pharmaceutical company Ocumension Therapeutics announced an agreement with Alcon under which OcuMension will acquire or secure commercialization rights in China to a portfolio of Alcon’s dry eye treatments and procedural drops, including establishe
- Bausch + Lomb Publishes Teneo Excimer Laser Clinical Trial Resultshttps://modernod.com/news/bausch-lomb-publishes-teneo-excimer-laser-clinical-trial-results/2482393/Bausch + Lomb announced the publication of clinical trial results for its Teneo Excimer Laser in the August issue of the Journal of Refractive Surgery. These findings supported the FDA approval of the Teneo platform for LASIK in January 2024, specifically for myopia and myopic astig
- Aldeyra Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of Reproxalaphttps://modernod.com/news/aldeyra-therapeutics-achieves-primary-endpoint-in-phase-3-dry-eye-disease-clinical-trial-of-reproxalap/2482391/Aldeyra Therapeutics announced the primary endpoint has been achieved in its phase 3 trial of investigational reproxalap for dry eye disease. In the randomized, double-masked, vehicle-controlled dry eye chamber clinical trial, reproxalap 0.25% was statistic
- Lensar's ALLY Adaptive Cataract Treatment System Approved in Europehttps://modernod.com/news/lensars-ally-adaptive-cataract-treatment-system-approved-in-europe/2482390/Lensar announced that the ALLY Adaptive Cataract Treatment System is now commercially available in Europe after receiving certification under the European Union’s Medical Device Regulation (MDR). Lensar is commercializing ALLY through its di
- FDA Notifies Ocular Therapeutix that SOL-R Trial is Appropriate as a Registrational Study in Wet AMDhttps://modernod.com/news/fda-notifies-ocular-therapeutix-that-sol-r-trial-is-appropriate-as-a-registrational-study-in-wet-amd/2482388/Ocular Therapeutix announced that it has received a written response from the FDA that the phase 3 SOL-R clinical trial is appropriate for use as the company’s second adequate and well controlled study of Axpaxli (axitinib intravitreal implant, also known as OTX-TKI) for the
- ASCRS Launches Summit Designed to Enhance Refractive Cataract Surgery Practiceshttps://modernod.com/news/ascrs-launches-summit-designed-to-enhance-refractive-cataract-surgery-practices/2482384/In a move to enhance the adoption of advanced-technology IOLs (AT IOLs), the American Society of Cataract & Refractive Surgery (ASCRS) announced a new educational initiative—the ASCRS Business of Refractive Cataract Surgery Summit (BRiCS). The summit aims to equip practices with th
- Novaliq Receives Positive CHMP Opinion for Vevizye in Dry Eye Diseasehttps://modernod.com/news/novaliq-receives-positive-chmp-opinion-for-vevizye-in-dry-eye-disease/2482383/Novaliq announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization in the European Union for dry eye drug Vevizye. Vevizye is intended for the treatment
- Enrollment Begins for Ocular Therapeutix’s Axpaxli Phase 3 SOL-R Wet AMD Studyhttps://modernod.com/news/ocular-therapeutixs-axpaxli-phase-3-sol-r-wet-amd-study-begins-enrollment/2482382/Ocular Therapeutix announced that the first patients have been enrolled in the phase 3 SOL-R clinical trial evaluating repeat dosing of Axpaxli (axitinib intravitreal implant, also known as OTX-TKI) for the treatment of patients with wet age-related macular degeneration (wet AMD). Accor
- Topcon Launches IS-6500 Ophthalmic Instrument Standhttps://modernod.com/news/topcons-is-6500-ophthalmic-instrument-stand-launched/2482381/Topcon Healthcare announced the launch of the IS-6500 digital instrument stand in the United States, Latin America, and Canada. The IS-6500 stand joins Topcon’s portfolio of ergonomic devices for eye exams. According to the company, the IS-6500 stand incorporates specialized